Ignite Creation Date:
2024-05-06 @ 6:54 PM
Last Modification Date:
2024-10-26 @ 2:57 PM
Study NCT ID:
NCT05828212
Status:
RECRUITING
Last Update Posted:
2023-04-25
First Post:
2023-04-12
Brief Title:
Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of RR Neuromyelitis Optica
Sponsor:
Zhejiang University
Organization:
Zhejiang University
Study Overview
Official Title:
A Study on the Safety and Efficacy of Chimeric Antigen Receptor T Cells in the Treatment of RecurrentRefractory Neuromyelitis Optica
Status:
RECRUITING
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single-arm open-label single-center phase I study The primary objective is to evaluate the safety of CD19 CAR-T therapy for patients with relapsed or refractory Neuromyelitis Optica and to evaluate the pharmacokinetics of CD19 CAR-T in patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None